Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Dr. Reddy's Launches Zenatane In US Market - Quick Facts

Dr. Reddy's Laboratories (RDY: Quote) announced it has launched Zenatane in 20 mg and 40 mg, a therapeutically equivalent generic version of Accutane, in the US market on March 28, 2013 following the approval by the FDA of ANDA for Zenatane 10 mg, 20 mg and 40 mg.

The company noted that total market had U.S. sales of approximately $309 million for the most recent twelve months ending January 2013 according to IMS Health.

Click here to receive FREE breaking news email alerts for and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and regularly increasing its annual earnings forecast, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's top-line and bottom-line results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.